QIAGEN N.V. Files Q3 2025 Report (6-K)
Ticker: QGEN · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1015820
| Field | Detail |
|---|---|
| Company | Qiagen N.V. (QGEN) |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $750.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
QIAGEN filed its 6-K for Q3 2025, standard foreign issuer report.
AI Summary
QIAGEN N.V. filed a Form 6-K on September 2, 2025, for the quarterly period ended August 31, 2025. The filing is a report of a foreign private issuer and includes information on "Other Information," "Signatures," and an "Exhibit Index." QIAGEN N.V. is incorporated in the Netherlands and its fiscal year ends on December 31.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding QIAGEN's financial reporting as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Numbers
- 001-38332 — Commission File Number (Identifies the specific SEC filing for QIAGEN N.V.)
Key Players & Entities
- QIAGEN N.V. (company) — Registrant
- 001-38332 (dollar_amount) — Commission File Number
- 20250831 (date) — Conformed Period of Report
- 20250902 (date) — Filed as of Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically providing information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
What period does this specific 6-K filing cover?
This Form 6-K filing covers the quarterly period ended August 31, 2025.
What is QIAGEN N.V.'s fiscal year end?
QIAGEN N.V.'s fiscal year ends on December 31.
Where is QIAGEN N.V. headquartered?
QIAGEN N.V. is headquartered in Venlo, The Netherlands.
What is the SIC code for QIAGEN N.V.?
The Standard Industrial Classification (SIC) code for QIAGEN N.V. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 290 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-08-29 18:12:04
Key Financial Figures
- $750.0 million — ase announcing a proposed offering of US$750.0 million of senior, unsecured net share settled
Filing Documents
- form6-kx2025convertibledebt.htm (6-K) — 21KB
- exhibit99108282025pressrel.htm (EX-99.1) — 29KB
- exhibit99208282025pressrel.htm (EX-99.2) — 21KB
- image_01.jpg (GRAPHIC) — 53KB
- image_0a.jpg (GRAPHIC) — 53KB
- 0001015820-25-000062.txt ( ) — 219KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date August 29, 2025 4 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press Release dated August 28, 2025 99. 2 Press Release dated August 28, 2025 5